<?xml version='1.0' encoding='utf-8'?>
<document id="27196064"><sentence text="The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway."><entity charOffset="18-29" id="DDI-PubMed.27196064.s1.e0" text="Clopidogrel" /><entity charOffset="31-38" id="DDI-PubMed.27196064.s1.e1" text="CYP2C19" /><pair ddi="false" e1="DDI-PubMed.27196064.s1.e0" e2="DDI-PubMed.27196064.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27196064.s1.e0" e2="DDI-PubMed.27196064.s1.e1" /></sentence><sentence text="The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1), forming clopidogrelic acid (SR26334) that is inactive"><entity charOffset="31-42" id="DDI-PubMed.27196064.s2.e0" text="clopidogrel" /><entity charOffset="60-75" id="DDI-PubMed.27196064.s2.e1" text="carboxylic acid" /><entity charOffset="107-125" id="DDI-PubMed.27196064.s2.e2" text="clopidogrelic acid" /><entity charOffset="127-134" id="DDI-PubMed.27196064.s2.e3" text="SR26334" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e0" e2="DDI-PubMed.27196064.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e0" e2="DDI-PubMed.27196064.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e0" e2="DDI-PubMed.27196064.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e0" e2="DDI-PubMed.27196064.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e1" e2="DDI-PubMed.27196064.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e1" e2="DDI-PubMed.27196064.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e1" e2="DDI-PubMed.27196064.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e2" e2="DDI-PubMed.27196064.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27196064.s2.e2" e2="DDI-PubMed.27196064.s2.e3" /></sentence><sentence text=" There is agreement on the structure of the active metabolite; however, there are differing views about the mechanism of its formation" /><sentence text=" Sanofi studied the conversion of clopidogrel to the active metabolite using human liver microsomes"><entity charOffset="34-45" id="DDI-PubMed.27196064.s4.e0" text="clopidogrel" /></sentence><sentence text=" It was concluded that 2-oxo-clopidogrel was formed via CYP3A oxidation"><entity charOffset="23-40" id="DDI-PubMed.27196064.s5.e0" text="2-oxo-clopidogrel" /></sentence><sentence text=" From a subsequent in vitro study by Sankyo of the metabolism of clopidogrel using recombinant DNA CYPs, it was concluded that CYP2C19 was the major oxidative pathway"><entity charOffset="65-76" id="DDI-PubMed.27196064.s6.e0" text="clopidogrel" /></sentence><sentence text=" Such CYPs can give false-negative results particularly with drugs such as clopidogrel that have high first-pass metabolism in the enterocyte"><entity charOffset="75-86" id="DDI-PubMed.27196064.s7.e0" text="clopidogrel" /></sentence><sentence text=" CYP3A is present in the enterocyte but not CYP2C19" /><sentence text=" However, the view that clopidogrel is a CYP2C19 substrate was reinforced by a finding that omeprazole, a CYP2C19 inhibitor, reduced the ability of clopidogrel to inhibit platelet aggregation"><entity charOffset="24-35" id="DDI-PubMed.27196064.s9.e0" text="clopidogrel" /><entity charOffset="92-102" id="DDI-PubMed.27196064.s9.e1" text="omeprazole" /><entity charOffset="148-159" id="DDI-PubMed.27196064.s9.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.27196064.s9.e0" e2="DDI-PubMed.27196064.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27196064.s9.e0" e2="DDI-PubMed.27196064.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27196064.s9.e0" e2="DDI-PubMed.27196064.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27196064.s9.e1" e2="DDI-PubMed.27196064.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27196064.s9.e1" e2="DDI-PubMed.27196064.s9.e2" /></sentence><sentence text=" The drug-drug interaction study of clopidogrel with omeprazole had the effect of reducing the area under the curve (AUC) of the clopidogrel active metabolite by 45%"><entity charOffset="36-47" id="DDI-PubMed.27196064.s10.e0" text="clopidogrel" /><entity charOffset="53-63" id="DDI-PubMed.27196064.s10.e1" text="omeprazole" /><entity charOffset="129-140" id="DDI-PubMed.27196064.s10.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.27196064.s10.e0" e2="DDI-PubMed.27196064.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27196064.s10.e0" e2="DDI-PubMed.27196064.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27196064.s10.e0" e2="DDI-PubMed.27196064.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27196064.s10.e1" e2="DDI-PubMed.27196064.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27196064.s10.e1" e2="DDI-PubMed.27196064.s10.e2" /></sentence><sentence text=" However, a drug interaction study with a CYP3A inhibitor, grapefruit juice, caused a 6-fold reduction in the AUC of the active metabolite" /><sentence text=" Clopidogrel is therefore now considered to be primarily a CYP3A4/5 substrate"><entity charOffset="1-12" id="DDI-PubMed.27196064.s12.e0" text="Clopidogrel" /></sentence><sentence text=" CYP2C19 has a minor role whose effect can be detected using a sensitive methodology such as platelet aggregometry" /><sentence text="" /></document>